Atezolizumab Plus FOLFOX Shows Promise in Stage III Mismatch Repair-Deficient Colon Cancer
A recent study published in the New England Journal of Medicine on March 26, 2026, details the promising results of combining atezolizumab with FOLFOX chemotherapy for patients with stage III mismatch repair-deficient (dMMR) colon cancer. The research, appearing in Volume 394, Issue 12, pages 1155-1166, suggests a potential new standard of care for this patient population.
Understanding Mismatch Repair Deficiency
Mismatch repair deficiency (dMMR) is a condition where cells have trouble correcting errors that occur during DNA replication. This leads to a higher mutation rate and can contribute to the development of certain cancers, including colon cancer. Approximately 15% of colon cancers are dMMR. National Cancer Institute
The Study Design and Findings
The study investigated the efficacy of adding atezolizumab, an immune checkpoint inhibitor, to the standard FOLFOX chemotherapy regimen. FOLFOX is a combination of three drugs: folinic acid, fluorouracil, and oxaliplatin. Researchers found that the addition of atezolizumab led to improved outcomes in patients with stage III dMMR colon cancer. While specific details of the improved outcomes require access to the full study, the publication in the New England Journal of Medicine signifies a potentially significant advancement in treatment.
Implications for Treatment
Traditionally, stage III colon cancer is treated with surgery followed by adjuvant chemotherapy, typically FOLFOX or CAPOX (capecitabine and oxaliplatin). The findings from this study suggest that adding atezolizumab to FOLFOX may enhance the effectiveness of this treatment approach for patients whose tumors exhibit dMMR. This is particularly important as dMMR status can predict response to immunotherapy.
What is Atezolizumab?
Atezolizumab is a monoclonal antibody that blocks the PD-L1 protein. PD-L1 helps cancer cells evade the immune system. By blocking PD-L1, atezolizumab allows the immune system to recognize and attack cancer cells. National Cancer Institute
Future Directions
Further research is needed to confirm these findings and to determine the optimal duration of atezolizumab treatment. Ongoing clinical trials will likely explore the use of atezolizumab in combination with other therapies for dMMR colon cancer, as well as its potential benefit in earlier stages of the disease. The March 26, 2026 publication in the New England Journal of Medicine marks an important step forward in personalized cancer treatment, tailoring therapies based on the specific genetic characteristics of a patient’s tumor.
Related reading